Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ Fri, 17 Sep 2021 13:37:59 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://parentsofallergicchildren.org/wp-content/uploads/2021/06/icon-5.png Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ 32 32 New NRS recommendations for rosacea https://parentsofallergicchildren.org/new-nrs-recommendations-for-rosacea/ https://parentsofallergicchildren.org/new-nrs-recommendations-for-rosacea/#respond Fri, 17 Sep 2021 13:37:59 +0000 https://parentsofallergicchildren.org/new-nrs-recommendations-for-rosacea/ An article published in the The Journal of Drugs in Dermatology has offered new recommendations for physicians to pay more attention to erythema associated with rosacea.1 The article was based on a National Rosacea Society (NRS) discussion of this key symptom after the recently updated standard classification system, standard management options, new findings from disease […]]]>

An article published in the The Journal of Drugs in Dermatology has offered new recommendations for physicians to pay more attention to erythema associated with rosacea.1

The article was based on a National Rosacea Society (NRS) discussion of this key symptom after the recently updated standard classification system, standard management options, new findings from disease burden studies, and significant advances in care.

The discussion was chaired by Richard Gallo, MD, PhD, president of dermatology at the University of California-San Diego, San Diego, Calif., And included Hilary Baldwin, MD, associate professor of dermatology at Rutgers Robert Wood Johnson Medical School , New Brunswick, New Jersey; Julie Harper, MD, president and owner of Birmingham Center for Dermatology and Skin Care, Vestavia Hills, Alabama; and Linda Stein Gold, MD, director of clinical research in dermatology at the Henry Ford Health System, Detroit, Michigan.

“Based on current scientific knowledge and clinical experience, rosacea is now classified as a single disorder with many potential phenotypes (signs and symptoms) that can occur in various combinations, with persistent facial erythema as the primary diagnostic sign. Said Gallo. “Combined with the results of studies showing the substantial psychological and social impact of facial erythema alone, these important findings have clarified our understanding of how and why all signs and symptoms of rosacea need to be managed effectively for optimal results. the patients. “

If either of the two phenotypes are present (i.e. erythema, thickening of the skin, papules, pustules, flushing, telangiectasias and certain ocular manifestations), they can be considered a diagnosis, according to the article. . Secondary phenotypes include burning, stinging, edema, and dryness.

According to the article, research suggested that the initial redness in rosacea is likely due to inflammation, which can cause other problems, and medications to treat the inflammation may be helpful for treatment. Data collected from NRS surveys as well as from disease burden studies have shown that persistent facial flushing, although often dismissed by physicians as a less severe phenotype, has a significant impact on the quality of life of patients. sufferers, often comparable to the impact of eczema, atopic dermatitis and psoriasis.

In a 2014 NRS survey, out of 1,675 patients diagnosed with rosacea, 82% of those with erythema said the disease had a negative impact on their general outlook on life and it was 90% for those with erythema. who presented with moderate to severe redness.2

The FDA has approved 2 therapies specifically for erythema caused by neurovascular deregulation in rosacea, brimonidine and oxymetazoline, both of which are alpha agonists.

According to research3, while brimonidine works relatively quickly, within 30 minutes some patients complain of excessive skin whitening, and it has been noted that exacerbations of redness can occur. While on the other hand, oxymetazoline has a maximum reduction in erythema at 3 hours, over a 24 hour period then returns to baseline and exacerbation of erythema has not been reported. .3

A combination of therapies can be used to treat different symptoms, such as anti-inflammatory treatments for redness around papules and pustules or light devices to eliminate telangiectasias and reduce erythema. The roundtable agreed that treating current phenotypes with target therapies would achieve the best results instead of using a single method. They also emphasized patient education on adherence, as it may be necessary to avoid triggers, regular use of treatment, and lifestyle changes to properly treat rosacea.

The roundtable was made possible by an educational grant from EPI Health.

Reference:

1. New Publication Tells Doctors About Facial Redness Associated With Rosacea. Rosacea.org. Posted August 23, 2021. Accessed September 13, 2021. https://www.rosacea.org/blog/2021/august/new-publication-updates-physicians-on-facial-erythema-in-rosacea

2. New Rosacea Investigation Shows Emotional Toll Of Face Redness Equals Impact Of Bumps And Pimples | rosacea. Org. Posted January 15, 2015. Accessed September 14, 2021. https://www.rosacea.org/press/2014/january/new-rosacea-survey-shows-emotional-toll-of-facial-redness-equals-impact- de-bumps-pimples

3. Gallo RL, Baldwin HE, Stein Gold L, Harper JC. Update on facial erythema in rosacea. J Drugs Dermatol 2021 August 1; 20 (8). Published online July 19, 2021. Accessed September 14, 2021. DOI: 10.36849 / JDD.6062


Source link

]]>
https://parentsofallergicchildren.org/new-nrs-recommendations-for-rosacea/feed/ 0
New cell type discovered in human skin to contribute to inflammatory skin diseases like atopic dermatitis and psoriasis https://parentsofallergicchildren.org/new-cell-type-discovered-in-human-skin-to-contribute-to-inflammatory-skin-diseases-like-atopic-dermatitis-and-psoriasis/ https://parentsofallergicchildren.org/new-cell-type-discovered-in-human-skin-to-contribute-to-inflammatory-skin-diseases-like-atopic-dermatitis-and-psoriasis/#respond Fri, 17 Sep 2021 04:03:26 +0000 https://parentsofallergicchildren.org/new-cell-type-discovered-in-human-skin-to-contribute-to-inflammatory-skin-diseases-like-atopic-dermatitis-and-psoriasis/ A team of international scientists and clinical experts have discovered a new type of cell in human skin that contributes to inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis (PSO). The results of their study were published in the Journal of Experimental Medicine in September 2021. The team is from A * STAR’s […]]]>

A team of international scientists and clinical experts have discovered a new type of cell in human skin that contributes to inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis (PSO). The results of their study were published in the Journal of Experimental Medicine in September 2021. The team is from A * STAR’s Singapore Immunology Network (SIgN), in collaboration with the Skin Research Institute of Singapore (SRIS), the Singapore National Skin Center, Department of Dermatology. , Kyoto University Graduate School of Medicine, Japan, and industry partner Galderma.

Chronic inflammatory skin diseases such as AD and PSO are characterized by the presence of activated T cell subtypes secreting pro-inflammatory cytokines in the skin. This T-cell mediated immune disruption is central to the pathogenesis of a wide range of inflammatory skin diseases. Thus, understanding the factors modulating the initiation and activation of T cells in healthy and diseased skin is essential to develop effective treatments for these diseases.

Recently, a single-celled RNA sequencing (RNA-seq) approach has been used to analyze human skin immune cells, including dendritic cells (DCs) and macrophages, which are cell populations controlling the activation of human skin cells. T lymphocytes. To address the role of DCs and macrophages in chronic inflammatory skin diseases, the team used a combination of complex approaches (single cell flow cytometry and RNA-seq of cells sorted by skin index healthy and sick human) to generate an impartial profile. landscape of DCs and macrophages, and to describe their distinct molecular signatures and proportions in skin lesions of patients with AD and PSO.

This revealed a significant enrichment in the proportion of CD14 + DC3 in the skin of PSO lesions, where they were one of the main cell types co-expressing IL1B and IL23A, two cytokines essential for the pathogenesis of PSO. This finding suggests that targeting CD14 + DC3 could represent a new therapeutic option in the treatment of PSO, and demonstrates the potential of the unicellular myeloid cell landscape database to provide important information on skin biology in the disease. health and disease.

Dr Florent Ginhoux, Principal Investigator, SIgN and final study author, said: “The results of this study are important as they will allow the design of new strategies to target or modulate myeloid cell populations for better results. health care for patients with atopic dermatitis. and psoriasis.

“The roles of antigen presenting cells in the development of inflammatory skin diseases remain unclear. This study clearly revealed the functions of each subset of antigen presenting cells, which is very informative and valuable for understanding the pathogenesis of atopic dermatitis and psoriasis. We anticipate that this study will lead to the design of a new treatment for refractory inflammatory skin diseases. said Professor Kenji Kabashima, Deputy Principal Investigator of SIgN and SRIS.

More information about the study, “Single-cell analysis of human skin identifies CD14 + type 3 dendritic cells co-producing IL1B and IL23A in psoriasis” can be found in the article published by the team in the Journal of Experimental Medicine: https: // pubmed. ncbi.nlm.nih.gov/34279540/

About the Agency for Science, Technology and Research (A * STAR)

The Agency for Science, Technology and Research (A * STAR) is Singapore’s leading public sector R&D agency. Through open innovation, we collaborate with our partners in the public and private sectors for the benefit of the economy and society. As a science and technology organization, A * STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and improves lives by improving societal outcomes in healthcare, urban living and sustainability. A * STAR plays a key role in nurturing scientific talent and leaders for the broader research community and industry. A * STAR’s R&D activities range from biomedical sciences to physical sciences and engineering, with research entities mainly located in Biopolis and Fusionopolis. For current news, visit www.a-star.edu.sg.

/ Public distribution. This material is from the original organization and may be ad hoc in nature, edited for clarity, style and length. See it in full here.


Source link

]]>
https://parentsofallergicchildren.org/new-cell-type-discovered-in-human-skin-to-contribute-to-inflammatory-skin-diseases-like-atopic-dermatitis-and-psoriasis/feed/ 0
Skin Discoloration Due To Eczema: Treatment, Types, And More https://parentsofallergicchildren.org/skin-discoloration-due-to-eczema-treatment-types-and-more/ https://parentsofallergicchildren.org/skin-discoloration-due-to-eczema-treatment-types-and-more/#respond Thu, 16 Sep 2021 17:10:44 +0000 https://parentsofallergicchildren.org/skin-discoloration-due-to-eczema-treatment-types-and-more/ Eczema is a common skin condition that causes itchy, dry, irritated lesions. Scratching the lesions can cause skin changes, including hypopigmentation and hyperpigmentation. Experts are not sure exactly what causes eczema. However, research suggests that genetics and environmental factors play a role. Eczema causes lesions on the skin that itch and dry. Many people feel […]]]>

Eczema is a common skin condition that causes itchy, dry, irritated lesions. Scratching the lesions can cause skin changes, including hypopigmentation and hyperpigmentation.

Experts are not sure exactly what causes eczema. However, research suggests that genetics and environmental factors play a role.

Eczema causes lesions on the skin that itch and dry. Many people feel the urge to scratch the affected skin, which can make the irritation worse. Eczema can spread to other parts of the body, change color and become infected.

The color change can be hypopigmentation, which is a loss of color, or hyperpigmentation, which is a darkening of the color.

Read on to learn more about the link between eczema and skin discoloration, treatment options, and more.

Eczema lesions, also called atopic dermatitis, can be itchy and uncomfortable. Itching eczema is a common behavior, but it can promote changes in the appearance and texture of the skin.

Eczema can cause two types of pigmentary changes in the skin: hypopigmentation and hyperpigmentation. Hypopigmentation is a loss of pigment or color, usually showing as patches lighter than a person’s skin tone. Hyperpigmentation refers to patches of skin that become darker than the skin around them.

Both hypo and hyperpigmentation are more visible on darker skin tones. However, they can appear on any skin tone.

People with eczema may find the change in the appearance of the skin painful and it can affect their quality of life. Even after treatment for eczema, the skin may not return to its previous color.

During an eczema flare, the body releases cytokines. In an effort to protect the body, they cause inflammation.

Cytokines trigger the release of melanocytes. These cells live in the skin and hair follicles and produce melanin, a pigment in the skin.

This reaction results in an increase in the production of pigment.

The darker a person’s skin, the more melanin it contains. As a result, people with darker skin release more pigment when the reaction occurs.

Eczema is different depending on a person’s skin type.

On fair skin, eczema usually causes inflamed pink or red patches that are dry and itchy. These lesions are more difficult to detect on dark skin.

When people with mild skin eczema lesions, hyper and hypopigmentation can occur. The pigmentation of the skin can progress gradually and its subtle changes make it difficult to detect.

People with dark skin are more likely to have hyper and hypopigmentation. They are also more likely to have follicular prominence, which is when the eczema presents as small, itchy bumps called papules. These mainly appear on the forearms and torso.

Hyperpigmentation

Darker patches of skin, or hyperpigmentation, occur as a result of inflammation. This prompts the melanocytes to increase the synthesis of melanin, which is the process of making pigments in the skin.

The increase in synthesis promotes the transfer of pigment to the epidermis, the top layer of the skin. If a person scratches or rubs their skin, it releases melanin.

Types of hyperpigmentation include:

Post-inflammatory pigmentation

Once an eczema flare has resolved, it can leave a darker spot on the skin. It is a post-inflammatory pigmentation.

Although it is temporary, it can persist for months, but it tends to last longer on dark skin tones.

Sunlight stimulates post-inflammatory pigmentation, so people should cover affected areas and use sun protection.

Lichenification

If a person rubs and scratches the affected areas of the skin, it can thicken. This can leave thick, leathery lesions with visible scratches, called lichenification.

These areas of hyperpigmentation can appear as gray on dark skin and dark pink on fair skin.

Hypopigmentation

Lighter skin patches, or hypopigmentation, can occur when a flare-up of eczema is resolving itself.

Hypopigmentation in eczema often presents as pityriasis alba, which is a low-grade eczema marked by pale, scaly patches. It typically causes between one and 20 rounded or oval patches on the neck, face, arms, and shoulders.

Tinea alba is more common on dark skin tones and occurs frequently after a person’s skin has been exposed to the sun. While dander and dryness may be more noticeable during the winter months, actual hypopigmentation is more common during the summer.

The lesions usually go away in 1 year, but they can take 2 to 3 years to go away.

There is no specific treatment for pigmentary changes in the skin. However, eczema is treatable in people of all skin types.

Hyper and hypopigmentation usually subside and go away on their own. Using a moisturizing cream or ointment can help with dryness, and sun protection will prevent hyper and hypopigmentation patches from getting worse.

If a person’s eczema or pigmentation does not resolve on their own, they may contact a doctor or dermatologist to make a treatment plan. This can include oral and topical steroids, non-steroidal creams, etc.

Hyper and hypopigmentation caused by eczema usually goes away on their own.

People who have difficulty managing their eczema may contact a doctor receive a diagnosis and establish a treatment plan. Additionally, people concerned about hyper and hypopigmentation plaques may also wish to see a doctor.

Eczema causes dry, itchy, and inflamed lesions. When irritated, the skin can develop patches of hyper or hypopigmentation.

There is no specific treatment for hypo or hyperpigmentation associated with eczema, and the conditions usually go away on their own over time. A person can see a dermatologist to treat their eczema.


Source link

]]>
https://parentsofallergicchildren.org/skin-discoloration-due-to-eczema-treatment-types-and-more/feed/ 0
Abbvie Selloff exaggerated, stocks remain undervalued: BMO https://parentsofallergicchildren.org/abbvie-selloff-exaggerated-stocks-remain-undervalued-bmo/ https://parentsofallergicchildren.org/abbvie-selloff-exaggerated-stocks-remain-undervalued-bmo/#respond Tue, 14 Sep 2021 19:21:21 +0000 https://parentsofallergicchildren.org/abbvie-selloff-exaggerated-stocks-remain-undervalued-bmo/ AbbVie’s (ABBV) – Get the report from AbbVie, Inc. The sale was overstated after a September 1 setback for its flagship immunology drug Rinvoq, and the stock remains undervalued, according to BMO analyst Gary Nachman. It has an outperformance rating and a price target of $ 133. The stock recently traded at $ 106.61, down […]]]>

AbbVie’s (ABBV) – Get the report from AbbVie, Inc. The sale was overstated after a September 1 setback for its flagship immunology drug Rinvoq, and the stock remains undervalued, according to BMO analyst Gary Nachman.


Source link

]]>
https://parentsofallergicchildren.org/abbvie-selloff-exaggerated-stocks-remain-undervalued-bmo/feed/ 0
Pfizer Nets World’s First Sign of Atopic Dermatitis for Xeljanz Cibinqo Track Amid FDA Clearance Timeframe https://parentsofallergicchildren.org/pfizer-nets-worlds-first-sign-of-atopic-dermatitis-for-xeljanz-cibinqo-track-amid-fda-clearance-timeframe/ https://parentsofallergicchildren.org/pfizer-nets-worlds-first-sign-of-atopic-dermatitis-for-xeljanz-cibinqo-track-amid-fda-clearance-timeframe/#respond Fri, 10 Sep 2021 15:42:40 +0000 https://parentsofallergicchildren.org/pfizer-nets-worlds-first-sign-of-atopic-dermatitis-for-xeljanz-cibinqo-track-amid-fda-clearance-timeframe/ As the FDA delays decisions on several JAK inhibitors due to safety concerns, its British counterpart has decided to give a new drug from Pfizer its first approval worldwide. Pfizer’s JAK inhibitor Cibinqo, also known as abrocitinib, has obtained UK Medicines and Health Products Regulatory Agency approval to treat moderate to severe atopic dermatitis, the […]]]>

As the FDA delays decisions on several JAK inhibitors due to safety concerns, its British counterpart has decided to give a new drug from Pfizer its first approval worldwide.

Pfizer’s JAK inhibitor Cibinqo, also known as abrocitinib, has obtained UK Medicines and Health Products Regulatory Agency approval to treat moderate to severe atopic dermatitis, the company.

Notably, the nod covers both the 100 mg and 200 mg doses of Cibinqo. After a post-market trial linked to Pfizer’s other JAK inhibitor, Xeljanz, with increased risks of cardiac side effects and cancer, concerns have grown over the approval of JAK drugs, especially at doses high.

Following the nod, Pfizer’s priority is to work with the National Institute for Health and Care Excellence and the Scottish Medicines Consortium to ensure regular access to Cibinqo, said Pfizer’s biopharmaceutical group president Angela Hwang in the communicated.

Pfizer has conducted a family of clinical trials dubbed JADE to support its Cibinqo records. In the first group of trials to read, the drug was shown to outperform placebo in cleansing the skin. In a bigger victory, Pfizer said a few days ago that the phase 3 JADE DARE trial found that 200 mg of Cibinqo, a once-a-day oral tablet, beat Sanofi’s successful injectable drug. and Regeneron, Dupixent, reducing itching and helping patients achieve near-complete skin lightening.

RELATED: Pfizer’s Abrocitinib Beats Blockbuster Dupixent in Phase 3 Eczema Trial, But Key Questions Remain

Pfizer has valued Cibinqo’s maximum sales potential at $ 3 billion, arguing that a large number of patients with atopic dermatitis do not receive a systemic agent. On a conference call with investors last October, Hwang said winning just an 8% share of the systemic atopic dermatitis market would mean $ 3 billion in revenue for Cibinqo at the peak.

But that optimistic outlook looks fragile after the FDA last week slapped new safety warnings and use restrictions on Xeljanz as well as AbbVie’s Rinvoq and Eli Lilly’s Olumiant. The FDA is updating the boxed warnings for drugs to include wording about the risk of serious heart events, cancer, blood clots, and death. In a more damning move, the FDA is limiting approved use of the drugs to patients who have tried but failed with at least one TNF blocker.

RELATED: FDA’s New JAK Safety Restrictions Are Problematic for AbbVie’s Rinvoq, But How Much?

The restrictions are causing problems for Cibinqo because the FDA views safety signals as a class-wide issue, even though the drugs target different members of the Janus kinase (JAK) family of enzymes. While Xeljanz appears to target JAK3, with weaker actions on JAK1 and JAK2, Cibinqo is designed as a specific inhibitor of JAK1, just like Rinvoq. In a note last Wednesday following the FDA announcement, SVB Leerink analyst Geoffrey Porges said he expects Cibinqo to get the same restrictions and labeling language.

After an FDA postponement in April, the agency again pushed back the application of the atopic dermatitis drug to July. The drug has no known new PDUFA data.


Source link

]]>
https://parentsofallergicchildren.org/pfizer-nets-worlds-first-sign-of-atopic-dermatitis-for-xeljanz-cibinqo-track-amid-fda-clearance-timeframe/feed/ 0
Atopic Dermatitis Epidemiology Forecast Report 2030 | Epidemiological analysis of atopic dermatitis 2030 | SearchInsight https://parentsofallergicchildren.org/atopic-dermatitis-epidemiology-forecast-report-2030-epidemiological-analysis-of-atopic-dermatitis-2030-searchinsight/ https://parentsofallergicchildren.org/atopic-dermatitis-epidemiology-forecast-report-2030-epidemiological-analysis-of-atopic-dermatitis-2030-searchinsight/#respond Tue, 07 Sep 2021 18:50:58 +0000 https://parentsofallergicchildren.org/atopic-dermatitis-epidemiology-forecast-report-2030-epidemiological-analysis-of-atopic-dermatitis-2030-searchinsight/ “DelveInsight LLP Commercial Research” DelveInsight’s report “Atopic Dermatitis (AD) – Epidemiological Forecast to 2030” provides an in-depth understanding of the historical and predicted atopic dermatitis (AD) epidemiology within 7 MM, i.e. United States, EU5 (Germany, Spain, Italy), France and United Kingdom) and Japan. DelveInsight has launched a new report on epidemiological predictions of atopic dermatitis, […]]]>

“DelveInsight LLP Commercial Research”

DelveInsight’s report “Atopic Dermatitis (AD) – Epidemiological Forecast to 2030” provides an in-depth understanding of the historical and predicted atopic dermatitis (AD) epidemiology within 7 MM, i.e. United States, EU5 (Germany, Spain, Italy), France and United Kingdom) and Japan.

DelveInsight has launched a new report on epidemiological predictions of atopic dermatitis, 2030.

Atopic dermatitis (eczema) is a condition that makes your skin red and itchy. It is common in children but can occur at any age. Atopic dermatitis is long lasting (chronic) and tends to worsen periodically. It can be accompanied by asthma or hay fever.

DelveInsight’s “Atopic Dermatitis Epidemiology Forecast to 2030” report provides an in-depth understanding of the disease, historical and predicted epidemiology of atopic dermatitis in the 7MM, i.e. US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Some of the highlights from the Atopic Dermatitis Epidemiology report:

  1. The total prevalent AD population in the United States was estimated to be 32,197,083 in 2020, including 13,313,991 cases in children and 18,883,091 cases in adults.

  2. The total population diagnosed with prevalent AD in the United States was 25,091,967 in 2020.

  3. The prevalent AD population in the United States is expected to increase at a CAGR of 0.55% during the forecast period 2021-2030.

  4. In 2020, the total prevalence of AD in adults in the United States was 5,684,566 in men and 9,421,907 in women.

Visit for more information on the epidemiology of atopic dermatitis

Scope of the report on the epidemiology of atopic dermatitis:

  1. The Atopic Dermatitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and modes of treatment.

  2. Atopic Dermatitis Epidemiology Report and Model provides an overview of risk factors and global trends for atopic dermatitis in the top seven markets (7MM: US, France, Germany, Italy, Spain, UK Uni and Japan)

  3. The report provides an overview of the historical and forecasted atopic dermatitis patient pool in seven major markets covering the US, EU5 (Germany, Spain, France, Italy, UK) and Japan

  4. Report Helps Recognize Growth Opportunities in 7MM Regarding Patient Population

  5. Report assesses risk and burden of disease and highlights unmet need for atopic dermatitis

  6. Report Provides Segmentation Of Atopic Dermatitis Epidemiology

Contents:

1. Key information

2. Executive summary of atopic dermatitis

3. Overview of the epidemiology of atopic dermatitis at a glance

4. Atopic Dermatitis: Background and Overview of the Disease

5. Epidemiology and patient population

6. Case reports

7. Country wise-epidemiology of atopic dermatitis

8. Annex

9. Features of DelveInsight

10. Warning

11.About DelveInsight

Associated reports:

Atopic Dermatitis Market

DelveInsight’s report “Atopic Dermatitis-Market Insights, Epidemiology, and Market Forecast — 2030” provides an in-depth understanding of 7MM, historical and predicted epidemiology as well as 7MM market trends in US, EU5 (Germany, France, Italy, Spain and United Kingdom),

Atopic dermatitis pipeline

DelveInsight’s “Atopic Dermatitis Pipeline Insight, 2021” report presents comprehensive information on current clinical development scenarios and growth prospects in the Atopic Dermatitis market. A detailed picture of the atopic dermatitis pipeline landscape is provided, which includes the disease overview and atopic dermatitis treatment guidelines.

Media contact
Company Name: DelveInsight Business Research LLP
Contact: Kritika rehani
E-mail: Send an email
Telephone: 9193216187
Address:304, boulevard S. Jones # 2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Source link

]]>
https://parentsofallergicchildren.org/atopic-dermatitis-epidemiology-forecast-report-2030-epidemiological-analysis-of-atopic-dermatitis-2030-searchinsight/feed/ 0
Sanofi finds Dupixent effective in atopic dermatitis in children under 5 https://parentsofallergicchildren.org/sanofi-finds-dupixent-effective-in-atopic-dermatitis-in-children-under-5/ https://parentsofallergicchildren.org/sanofi-finds-dupixent-effective-in-atopic-dermatitis-in-children-under-5/#respond Tue, 07 Sep 2021 03:12:09 +0000 https://parentsofallergicchildren.org/sanofi-finds-dupixent-effective-in-atopic-dermatitis-in-children-under-5/ Sanofi-Aventis Korea has confirmed the safety and efficacy profile of Dupixent (ingredient: dupilumab) in the treatment of children with moderate to severe uncontrolled atopic dermatitis in recent studies. The company has conducted LIBERTY AD PRESCHOOL Phase 2/3 clinical trials in 162 patients aged six months to five years. Sanofi-Aventis Korea said it has confirmed that […]]]>

Sanofi-Aventis Korea has confirmed the safety and efficacy profile of Dupixent (ingredient: dupilumab) in the treatment of children with moderate to severe uncontrolled atopic dermatitis in recent studies.

The company has conducted LIBERTY AD PRESCHOOL Phase 2/3 clinical trials in 162 patients aged six months to five years.

Sanofi-Aventis Korea said it has confirmed that Dupixent (ingredient: dupilumab) reduces signs and symptoms of moderate to severe atopic dermatitis in children as young as six months old.

In the phase 3 study, Sanofi-Aventis Korea found that a combination of Dupixent and low-dose topical corticosteroids (TCS) improved disease severity, skin damage and quality of life compared to monotherapy TCS at week 16.

During the study, 28% of patients receiving Dupixent met the primary endpoint with few or no lesions, while only 4% met the primary endpoint in the placebo group.

Outside the United States, the proportion of patients showed an improvement of 75% or more in the Eczema Severity Index (EASI), the primary endpoint, was 53% in the Dupixent group and by 11% in the placebo group.

“Children are significantly affected during their childhood when they are diagnosed with moderate to severe atopic dermatitis in the first few months of life, and their parents and caregivers are challenged to find safe and effective treatment options,” said Dr John Reed, Global Head of Research and Development at Sanofi.

Dr Reed added that since standard care for children with atopic dermatitis could damage the skin and potentially impact their growth if used long-term, the company was heartened by the results of the recent studies showing how Dupixent demonstrated potential as a new option. for very young patients.

“At the start of clinical trials, more than half of patients’ bodies were covered with the disease, and nearly a third of them had a history of using immunosuppressive drugs,” Regeneron President and CSO said , George D. Yancopoulos. “Our data showed that Dupixent significantly reduced the impact of atopic dermatitis in young children and their families by rapidly improving symptoms and outcomes.”

Sanofi plans to present the detailed results of the study at medical conferences and submit them to regulatory authorities in each country.

The Department of Food and Pharmaceutical Safety has yet to approve Dupixnet for patients aged six months to five years.


Source link

]]>
https://parentsofallergicchildren.org/sanofi-finds-dupixent-effective-in-atopic-dermatitis-in-children-under-5/feed/ 0
Eczema: researchers discover a “new approach” to treat sensitive skin https://parentsofallergicchildren.org/eczema-researchers-discover-a-new-approach-to-treat-sensitive-skin/ https://parentsofallergicchildren.org/eczema-researchers-discover-a-new-approach-to-treat-sensitive-skin/#respond Tue, 31 Aug 2021 20:50:00 +0000 https://parentsofallergicchildren.org/eczema-researchers-discover-a-new-approach-to-treat-sensitive-skin/ Most people with eczema, especially atopic dermatitis, tend to develop sensitive skin before the age of five. Symptoms include dry, itchy skin. The Mayo Clinic noted that “red to brownish gray spots” can appear on the skin. Also, for some people, small raised bumps may appear that leak fluid and form a scab when scratched. […]]]>

Most people with eczema, especially atopic dermatitis, tend to develop sensitive skin before the age of five. Symptoms include dry, itchy skin. The Mayo Clinic noted that “red to brownish gray spots” can appear on the skin. Also, for some people, small raised bumps may appear that leak fluid and form a scab when scratched.

Dr Granville added, “Previous work had suggested that Granzyme B levels correlated with the degree of itching and severity of disease in patients with atopic dermatitis.

“Our study provides evidence that topical drugs targeting Granzyme B could be used to treat patients with eczema and other forms of dermatitis.”

A common treatment for eczema is corticosteroid creams, which can “lighten the skin” when used for a long time.

Thin skin is said to be more prone to damage and infection, which is why research has looked into new areas of treatment, such as targeting the enzyme Granzyme B.

However, the researchers see “great promise in this line of research and are pursuing new clinical trials on granzyme B and granzyme B inhibitors.”

During this time, to help relieve any sensitive skin caused by atopic dermatitis, you can:

  • Using emollients
  • Topical corticosteroids
  • Antihistamines.

The NHS added that it would be helpful to avoid known triggers and wear medicated bandages.


Source link

]]>
https://parentsofallergicchildren.org/eczema-researchers-discover-a-new-approach-to-treat-sensitive-skin/feed/ 0
Regeneron Pharmaceuticals is my value share of the week https://parentsofallergicchildren.org/regeneron-pharmaceuticals-is-my-value-share-of-the-week/ https://parentsofallergicchildren.org/regeneron-pharmaceuticals-is-my-value-share-of-the-week/#respond Fri, 27 Aug 2021 20:54:17 +0000 https://parentsofallergicchildren.org/regeneron-pharmaceuticals-is-my-value-share-of-the-week/ Regeneron Pharmaceuticals, Inc. (REGN) has grown in popularity over the past year due to its COVID 19 cocktail treatment. But the company is not a trick pony. He has more than a few hit drugs, with more on the way. The best part is that the stock is quite undervalued. Read on to find out […]]]>

Regeneron Pharmaceuticals, Inc. (REGN) has grown in popularity over the past year due to its COVID 19 cocktail treatment. But the company is not a trick pony. He has more than a few hit drugs, with more on the way. The best part is that the stock is quite undervalued. Read on to find out why this stock belongs in your portfolio.

Regeneron Pharmaceuticals, Inc. (REGN) discovers, develops and markets products that fight eye disease, cardiovascular disease, cancer and inflammation. The company has several products marketed, including Eylea, approved for wet age-related macular degeneration and other eye diseases, Praluent for lowering LDL cholesterol, and Dupixent for atopic dermatitis, asthma and nasal polyposis.

The company is also developing monoclonal antibodies with Sanofi in immunology and cancerology. REGN also develops bispecific antibodies and antibody cocktails with other collaborators and independently. However, its main growth driver is Eylea, which continues to generate strong revenues through the continued expansion of its labels.

Eylea is approved in the US, EU, Japan, and other countries to treat age-related neovascular macular degeneration, diabetic macular edema, and macular edema. Demographic trends are driving growth in the United States, including an aging population and an increasing prevalence of diabetes.

REGN is also working to expand the drug’s label to other indications. This should further boost sales. For example, the FDA has approved a 12-week dosing interval for injecting Eylea in patients with wet AMD. The drug has also been approved for the treatment of diabetic retinopathy. Further expansion of the label into other indications should allow the drug to gain access to more patients, which would increase the profit potential.

The company also has the approval of Dupixent Injection for the treatment of adults with moderate to severe atopic dermatitis and asthma. Absorption was strong for atopic dermatitis and asthma. Dupixent has also been approved in Europe. Like Eylea, continued brand expansion is expected to further boost sales.

Additional drugs also generate income for the company. For example, Kevzara has been approved in the United States for the treatment of adult patients with moderate to severe active rheumatoid arthritis. A few years ago, the FDA approved Libtayo to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

The initial adoption of Libtayo was strong, which is why REGN is working on expanding its label. The company also has a strong pipeline. REGN is resuming the recruitment of patients with follicular lymphoma and diffuse large B-cell lymphoma in its monotherapy trials with odronextamab.

But REGN’s most popular offering right now is the COVID 19 REGEN-COV treatment. The FDA has granted emergency use authorization for the antibody cocktail of two monoclonal antibodies (casirivimab and imdevimab). The treatment was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.

The treatment had a good quarter as it generated total sales of $ 3 billion in the quarter. During the quarter, the company fulfilled its second agreement with the US government to manufacture and deliver 1.25 million doses of REGEN-COV.

This helped generate substantial growth for the company during the quarter. Earnings were $ 25.80 per share, up 260% year-over-year. Revenue jumped 163% year over year. Even excluding REGEN-COV, sales rose 22% to $ 2.38 billion, driven by strong demand for Eylea and Dupixent.

REGN has an overall rating of B, resulting in a purchase rating in our POWR rating system. The company has a growth rating of B, in part due to growth in the last quarter. Analysts expect sales to grow a further 28.8% year-over-year in the current quarter and 55.5% for the year. REGN also has a value rating of B due to its current rating.

The stock has a trailing P / E of 11.98 and a forward P / E of 12.48; both are very attractive numbers. Its price-to-sales ratio of 6.1 is also well below the industry average. If we consider the price targets of analysts, the stock is undervalued by up to 24%. We also provide Momentum, Stability, Feeling, and Quality Notes for REGN, which you can find here.

REGN is ranked # 11 in the biotechnology industry. For more leading actions in this industry, Click here.

REGN is just one of the stocks in my POWR Value portfolio. This is where I combine my many years of investing experience with the Top 10 Value Stocks strategy, which has annual returns of 38.63%, to provide investors with the best value stocks for the current market.

If you would like to see the current portfolio of 14 stocks and be alerted to our upcoming trades in a timely manner, consider starting a 30 day trial by clicking the link below.

About the POWR Value newsletter and the 30 day trial

REGN shares rose $ 0.08 (+ 0.01%) in after-hours trading on Friday. Year-to-date, REGN has gained 37.30%, compared to a 21.22% increase in the benchmark S&P 500 over the same period.

About the Author: David Cohne

David Cohne has 20 years of experience as an investment analyst and writer. He is the chief value strategist for StockNews.com and the publisher of the POWR Value newsletter. Prior to StockNews, David spent eleven years as a consultant providing outsourced investment research and content to financial services firms, hedge funds and online publications. David enjoys researching and writing about stocks and markets. It takes a fundamental quantitative approach in evaluating stocks for readers.

Following…

The post office Regeneron Pharmaceuticals is my value share of the week appeared first on StockNews.com


Source link

]]>
https://parentsofallergicchildren.org/regeneron-pharmaceuticals-is-my-value-share-of-the-week/feed/ 0
Cracked skin: causes, diagnosis and treatment https://parentsofallergicchildren.org/cracked-skin-causes-diagnosis-and-treatment/ https://parentsofallergicchildren.org/cracked-skin-causes-diagnosis-and-treatment/#respond Tue, 24 Aug 2021 20:28:26 +0000 https://parentsofallergicchildren.org/cracked-skin-causes-diagnosis-and-treatment/ Cracked skin can just be dry skin on the hands, heels of the feet, or lips that need extra hydration and hydration. However, cracked skin can also be a sign of an infection or even something more. Find out the causes, symptoms, and treatment for cracked skin. Advertising Catherine Falls / Getty Images Causes and […]]]>

Cracked skin can just be dry skin on the hands, heels of the feet, or lips that need extra hydration and hydration. However, cracked skin can also be a sign of an infection or even something more.

Find out the causes, symptoms, and treatment for cracked skin.

Advertising Catherine Falls / Getty Images


Causes and symptoms of cracked skin

When the skin becomes dry, it is more likely to crack, peel, flake, and become irritated.

Depending on the cause of the cracked skin, you may notice other symptoms. Some skin conditions cause many of the same symptoms. Therefore, paying attention to any signs that accompany your cracked skin will help detect the cause.

Dry skin

Dry skin is medically known as xerosis and results from a decrease in the water content in the top layer of your skin. Healthy skin has an outer layer called the skin barrier. It helps prevent water loss from your body and also prevents toxins, infections, allergens, and chemicals from entering your body.

Sometimes your skin barrier weakens, resulting in dry skin. Common causes of dry skin include:

  • Pollution and chemicals: Body washes, dish soap, face wash, scrubs, household cleaners, and air pollution contain chemicals that could dry out your skin.
  • Sun exposure: Sunburn or even just spending time in the sun without sunscreen can increase oil and water loss from your skin.
  • Cold weather and indoor heating: The combination of cold temperatures and low humidity outside and low humidity from indoor heating often dries out the skin.
  • Hot water: Exposure to hot water when showering and washing dishes wicks excess moisture from your skin.
  • Being wet for long periods of time: Spending hours swimming or wearing wet clothes can dry out, wrinkle, and irritate the skin.
  • Clothes, shoes or barefoot walking: Pressure from your clothes, such as straps or walking barefoot, can irritate your skin, causing rashes, blisters, or cracks on your skin.

Eczema

Eczema, also called atopic dermatitis, is an inflammatory skin condition that results in dry, cracked, and red skin. It often affects the skin of the face, hands, arms and behind the knees.

Common symptoms of eczema include:

  • Itchy skin
  • Dry and cracked plates
  • Redness
  • Bulbs
  • Peeling

Psoriasis

Psoriasis is a disease in which skin cells build up, forming dry, scaly patches. It is thought to be caused by an autoimmune response, in which your body mistakenly attacks healthy cells. Psoriasis can be made worse by stress, infections, or cold air.

The patches usually occur on the scalp, elbows, knees, and lower back. Other symptoms of psoriasis can include redness, silvery-white scales, and itching.

Diabetic neuropathy

Uncontrolled diabetes can lead to a complication of neuropathy, which is nerve damage to the feet or hands. Additionally, people with uncontrolled diabetes are more likely to get infections on their feet and have cracked heels.

Other symptoms of diabetic neuropathy include:

  • Poorly healing wounds
  • Numbness in the hands or feet
  • Pain or weakness in the feet, legs, or hands
  • Calluses

Fungal infections

Skin infections such as athlete’s foot or other yeast infections can cause redness, itching, rash, and cracking of the skin.

Fungal infections are more common in people with diabetes or in people who constantly wear wet clothes (swimmers, runners, cyclists).

Exfoliative dermatitis

Erythroderma, or exfoliative dermatitis, is a serious disorder of skin cells that causes exfoliation or loss of the top layers of your skin. It can cover 90% or more of your body and can be due to medications, pre-existing skin conditions, or even cancer. Common symptoms of erythroderma include:

  • Red and cracked plaques
  • White or yellow scaly patches
  • Skin that looks shiny or thin
  • A feeling of tightness of the skin
  • Hair loss
  • Dry or brittle nails

Diagnosis and treatment of cracked skin

To diagnose your cracked skin, a healthcare professional will examine you and ask you questions about your medical history, such as:

  • When did the symptoms appear?
  • Is the area hot or itchy?
  • Have you noticed any bleeding, oozing, or pus near areas of dry skin?
  • Do you have any allergies?
  • Have you used any new products recently?

A healthcare professional may also take a sample of affected skin or any fluid around the area to check for infection.

Once diagnosed, a healthcare professional will help you develop a treatment plan. Cracks caused simply by dry skin are usually easily treated at home with moisturizers or other remedies that tackle the root cause of your dry skin.

Home remedies for dry, cracked skin include:

  • Use of physical or chemical exfoliators on dry areas: These will help remove all layers of dead skin from the surface, including dry areas. Just be careful that they aren’t too harsh, or they could make your skin drier.
  • Regularly use moisturizers: Creams with ingredients like coconut oil, shea butter, olive oil, and aloe vera can help soothe and hydrate the skin.
  • Vaseline: The skin does not easily absorb petroleum jelly, but it is good to use it in addition to moisturizers to help retain moisture.
  • Hydrocortisone cream: Hydrocortisone cream helps relieve redness and itching. It is a topical steroid that calms inflammation of the skin. Soft strengths are available over the counter. Follow the manufacturer’s directions for use and talk to your healthcare professional about the best option for your skin.
  • Antifungal cream or spray: If you have a fungal infection, such as athlete’s foot, there are over-the-counter anti-fungal medications to help kill the fungus. If it doesn’t go away, ask your doctor about other options.

Although some skin conditions that cause cracking of the skin can be treated at home, tell your doctor if you notice these signs of infection:

  • Redness
  • Swelling
  • Skin warm to the touch around the affected area
  • Fever
  • Pus or oozing in or around the area

If you are not sure what is causing your dry skin, it may be helpful to talk to your primary care doctor or a dermatologist, a specialist in skin, hair and nail conditions, to make sure that you are treating the disease properly.

Ways to prevent cracked skin

Some types of cracked skin can be avoided by taking care of your skin and general health. Here are some tips to prevent cracking of the skin:

  • Moisturize areas that often get dry.
  • Use a thicker moisturizer during the cold months.
  • Use petroleum jelly to lock in moisture and as a barrier against cold or dry air.
  • Wear gloves and other protective clothing if exposed to chemical irritants or the weather.
  • Change wet or sweaty clothes as soon as possible.
  • Use a humidifier to humidify indoor air during dry months.
  • Work with your doctor to control other medical conditions like diabetes.

A word from Verywell

Dry, cracked skin can be itchy and sometimes embarrassing to experience. Most of the time, cracked skin is simply caused by extremely dry skin, although sometimes it can be due to other conditions.

You can treat cracked skin by applying moisturizer to soothe the skin and petroleum jelly as a barrier, and avoiding skin irritants. If your skin is not improving, or if you notice any signs of infection, talk to your healthcare professional.

Frequently Asked Questions

Are there any home remedies for cracked skin?

Yes. Some home remedies for cracked skin include regular hydration, wearing protective clothing when exposed to the cold, taking shorter showers with warm (not hot) water, using petroleum jelly or of coconut oil on a moisturizer on the skin, putting a humidifier in your room during the dry months and avoiding products that irritate your skin.

How to remove cracked skin from your heels?

You can remove the cracked skin from your heels with chemical or physical exfoliators. Chemical exfoliators that can help dry skin include glycolic acid and lactic acid. You can also rub a loofah, pumice stone, or body scrub on your heels to remove dead skin cells.

What’s the fastest way to treat cracked skin?

You can treat dry skin quickly by treating and removing anything that irritates your skin, like harsh cleansers or soaps, hot showers, long showers, dry air, and exposure to cold.

Go to hot showers for 5-10 minutes, apply moisturizer immediately after washing, wear gloves in cold weather, use humidifiers, change wet clothes as soon as possible, and use gentle products.


Source link

]]>
https://parentsofallergicchildren.org/cracked-skin-causes-diagnosis-and-treatment/feed/ 0